Browse the evidence

Baseline body mass index, race, and age seem less relevant for predicting weight-loss response to liraglutide.

Providers may deprioritize these factors when assessing weight loss potential with liraglutide.

Two days of recovery with optimal energy availability (OEA) partially restored performance but did not fully recover it to the level of the OEA group.

Recovery strategies should include optimal energy availability to aid performance recovery after low energy phases.

High raw and absolute mean RIR accuracy for 1-RIR and 3-RIR predictions were observed.

The observed accuracy metrics can help inform training protocols.

Four positive signals were found at the system organ classes level for tirzepatide.

Monitoring for specific adverse events is crucial for patients on tirzepatide.

Two patients achieved significant weight loss of 16% and 12.6% in under 9 months using semaglutide.

Clinicians can expect significant weight loss outcomes in similar patients using semaglutide.

Most ultraprocessed foods overlap with foods high in saturated fat, added sugars, and sodium.

Practitioners should consider the nutritional content of UPFs when advising clients.

Tirzepatide was recently approved by the FDA for the management of type 2 diabetes.

Tirzepatide can be utilized in clinical settings for managing type 2 diabetes, with potential implications for weight loss.

Metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care.

Practitioners should consider metabolic and bariatric surgery as a viable option for reducing cancer risk in obese patients.

No significant differences in adverse events were observed between semaglutide and comparator groups.

This suggests that semaglutide is as safe as other treatments in terms of adverse events.

Fifty-six studies reported statistically significant findings in outcome measures.

Interventions can lead to measurable improvements in health outcomes.

Considering interactions among dietary components can help reconcile different models of obesity.

Practitioners should consider dietary interactions when developing obesity interventions.

Reductions in fat mass were similar across all protein intake groups, with LP, MP, and HP showing reductions of 1.7%, 3.7%, and 3.1% respectively (P > 0.05).

Fat loss outcomes may not significantly differ based on protein intake levels in older women undergoing resistance training.

Tirzepatide achieved similar 12-month TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04).

Tirzepatide may be a viable alternative for weight loss in patients post-sleeve gastrectomy, potentially outperforming semaglutide.

Both FDA-approved gastric balloon systems (gas-filled IGB and fluid-filled IGB) had the same effectiveness in terms of percent total body weight loss at balloon removal.

Both balloon systems can be considered equally effective for weight loss.

The implementation of a pharmacist-led weight management clinic resulted in an estimated cost savings of $101,985.66.

Pharmacist involvement can lead to significant cost savings in weight management programs.

Discontinuation rates were strongly associated with copayment amount, increasing from 41% in the lowest quintile to 51% in the highest quintile.

Financial considerations significantly impact patient adherence to semaglutide treatment.

Minimally invasive bariatric surgeries, endoscopic procedures, fecal microbiota transplants (FMTs), and pharmaceuticals like GLP-1 receptor agonists show promising results for obesity treatment.

Practitioners should consider these innovative treatment options for obesity management.

Bariatric surgery is the most cost-effective definitive treatment for all classes of obesity.

Healthcare systems should prioritize bariatric surgery as a treatment option for obesity.

Participants enrolling during program periods with access to a larger number of stores had ≤14.5% absolute higher redemption rates and 5-fold greater likelihood of shopping each month than those enrolled with fewest locations.

Increasing the number of stores available for produce prescription programs may enhance redemption rates and shopping frequency.

Redemption rates increased over time for participants in the program, rising from 31% in month 1 to 88% in month 24.

Longer participation in produce prescription programs is associated with significantly higher redemption rates.

There is a strong need for multimodal therapeutic approaches to address obesity.

Therapists should implement diverse strategies to effectively manage obesity.

There are no indications of additional risk for people with HIV using liraglutide and semaglutide.

Liraglutide and semaglutide can be considered safe for use in HIV patients without additional risk.

Employment increased by 2.9 percentage points for the intensive lifestyle intervention (ILI) group relative to controls.

Implementing intensive lifestyle interventions may improve employment rates among individuals with type 2 diabetes.

An intensive lifestyle intervention was associated with higher levels of employment.

Healthcare providers should consider lifestyle interventions as a means to improve employment outcomes for patients with type 2 diabetes.